Most Favored Nation (MFN)

Your go-to resource for better market access

Navigating the evolving MFN landscape

Strategic insights and solutions for pharmaceutical and biotech companies

Most Favored Nation (MFN) pricing marks a tectonic shift in the US healthcare landscape with global P&MA implications. For the first time US prices are interconnected with prices outside the U.S., and not just at the list price level, but also on the net price level. As US revenues typically make up 60-70% of an asset’s value, manufacturers must navigate this sea of change with a robust strategy, or risk an epic failure by launching innovative pharmaceuticals on a global base without taking MFN into account across a product’s full product lifecycle. 

This hub brings together the latest insights, policy updates, and expert analysis to help you stay informed, respond with confidence, and make better pricing and market access decisions.

Our services and capabilities

The Simon-Kucher MFN Monitor

Stay ahead of evolving MFN pricing risks with real-time intelligence from Simon-Kucher. We track policy developments, global pricing strategies and time-to-market information across the US and the 19 reference markets to help inform global pricing and launch decisions.

MFN risk assessment and advanced-analytics modeling

Quantify the potential impact of MFN on your portfolio with scenario-based modeling and analytics. Use Simon-Kucher's proprietary digital LS Genius MFN tools for Generous, Globe, Guard and Prospective MFN to help to assess pricing risks across existing product portfolios and pipeline products, to evaluate global pricing decisions, and to model strategic scenarios to support informed commercial decisions.

Public policy engagements

Support the identification and execution of targeted policy engagement initiatives to address market and policy developments that could materially influence MFN exposure. Simon-Kucher helps clients evaluate emerging policy risks, prioritize engagement opportunities, and shape stakeholder strategies to protect long-term pricing as well as US and ex-US market access objectives.

Reassessing and adapting BD&L strategy and new product planning

Integrate MFN considerations into business development, licensing, and pipeline planning decisions. We help clients assess asset attractiveness, forecast future pricing and access implications, and optimize investment decisions considering an evolving global pricing landscape.

Updating governance and decision-making processes

Revise pricing governance frameworks and cross-functional decision-making processes to ensure MFN implications are systematically considered. This includes updating the global pricing philosophy, pricing governance, approval mechanisms, escalation pathways, and key business processes to support informed and timely decisions.

MFN risk mitigation solutions

Develop practical strategies to reduce MFN-related pricing risks while protecting global asset value. Simon-Kucher evaluates a range of mitigation options, including pricing policy adaptations, launch sequencing, alternative access and distribution models, and market-specific interventions, to identify the right approach for the launch of each product in each market.

Latest insights

The Simon-Kucher MFN Monitor

Discover our proprietary tracker of global pricing, launch timelines, and policy developments across the US and MFN-19 markets.

Contact our experts

Senior Partner
Boston, USA
Managing Partner
Boston, USA
Senior Partner
Cologne, Germany
Senior Partner
Munich, Germany

Better Market Access in Pharma

Discover tangible solutions that are effectively implementable. Dive deep into our comprehensive insights on pharmaceutical market excellence, designed to drive growth for your pharma business.
Kontakt

Nehmen Sie Kontakt zu uns auf, unser Team berät Sie gerne.